Gokhan Tulunay
Research Subjects
Gokhan Tulunay has a total of 363 co-authors. Here are the top co-authors by number of shared publications:
Taner Turan
Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital , Ankara, Turkey
35 shared publicationsNurettin Boran
Gynecologic Oncology Department, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Ankara - Turkey
26 shared publicationsAlper Karalok
Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital , Ankara, Turkey
22 shared publicationsTolga Tasci
Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital , Ankara, Turkey
21 shared publicationsIsin Ureyen
Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital , Ankara, Turkey
16 shared publicationsM. Faruk Kose
14 shared publications
Latest Publications
- Open Access
- 27 April 2022
- Published by MedCrave Group Kft. in MOJ Women s Health
- Vol. 11 (1) , 21-26
Total pelvic organ prolapses and its surgery with meses: Adventure or cure?
Total pelvic organ prolapse is a condition that is frequently seen in elderly women and presents with defecation and urinary system dysfunctions and impairs quality of life. Study objective: While preparing this study with its results, our aim was to evaluate the positive effect of minimally invasive repair with mesh on impaired organ functions, anatomy and quality of life in patients with obvious pelvic organ prolapse. Design: Among the people who applied to the gynecology and proctology outpatient clinic within a certain time period, the files of the patients with complaints stated below were scanned. The determined parameters were collected and evaluated prospectively. Statistical study was done with SPSS 15.0. Patients: The patients were those who applied to the gynecology and proctology outpatient clinic. Patients with complaints of vaginal/pelvic fullness, constipation, fecal incontinence, and prominent vaginal tissue prolapse between the legs were selected to participate in the study. Measurement and main results: Laparoscopic promontofixation was performed on 8 patients with overt pelvic organ prolapse (POP-Q III and IV), among those who applied to the outpatient clinic with complaints of pelvic fullness, pain, difficult urinating, constipation or overt organ prolapse between 2015-19. Pelvic dysfunction, difficult urination and defecation function of these patients were evaluated. Pelvic organ distress, urinary distress, and colorectal distress inventory questionnaires were administered to the patients before and during follow-up and the measurements were compared. Complications related to surgery and recurrence was also monitored during follow-up. In those patients followed for an average of 29.5 months. Surgical recurrence was observed in one patient and various surgical complications were observed in 4/8 patients. At the end of the comparative evaluation of the questionnaires, it was determined that the patients' pelvic function and difficult urination improved with surgery. However, an improvement could not be demonstrated in defecation function. Conclusion: Laparoscopic promontofixation should be kept in mind as a surgical method that can provide functional improvement in selected patients with overt pelvic organ prolapse.
- 27 April 2022
- Published by MedCrave Group Kft. in MOJ Women s Health
- Vol. 11 (1) , 21-26
Open AccessTotal pelvic organ prolapses and its surgery with meses: Adventure or cure?
Total pelvic organ prolapse is a condition that is frequently seen in elderly women and presents with defecation and urinary system dysfunctions and impairs quality of life. Study objective: While preparing this study with its results, our aim was to evaluate the positive effect of minimally invasive repair with mesh on impaired organ functions, anatomy and quality of life in patients with obvious pelvic organ prolapse. Design: Among the people who applied to the gynecology and proctology outpatient clinic within a certain time period, the files of the patients with complaints stated below were scanned. The determined parameters were collected and evaluated prospectively. Statistical study was done with SPSS 15.0. Patients: The patients were those who applied to the gynecology and proctology outpatient clinic. Patients with complaints of vaginal/pelvic fullness, constipation, fecal incontinence, and prominent vaginal tissue prolapse between the legs were selected to participate in the study. Measurement and main results: Laparoscopic promontofixation was performed on 8 patients with overt pelvic organ prolapse (POP-Q III and IV), among those who applied to the outpatient clinic with complaints of pelvic fullness, pain, difficult urinating, constipation or overt organ prolapse between 2015-19. Pelvic dysfunction, difficult urination and defecation function of these patients were evaluated. Pelvic organ distress, urinary distress, and colorectal distress inventory questionnaires were administered to the patients before and during follow-up and the measurements were compared. Complications related to surgery and recurrence was also monitored during follow-up. In those patients followed for an average of 29.5 months. Surgical recurrence was observed in one patient and various surgical complications were observed in 4/8 patients. At the end of the comparative evaluation of the questionnaires, it was determined that the patients' pelvic function and difficult urination improved with surgery. However, an improvement could not be demonstrated in defecation function. Conclusion: Laparoscopic promontofixation should be kept in mind as a surgical method that can provide functional improvement in selected patients with overt pelvic organ prolapse.
- 28 February 2021
- Published by Balikesir Medical Journal in Balıkesir Medical Journal
- Vol. 5 (1) , 43-53
Preoperatif Nötrofil/Lenfosit, Lenfosit/Monosit ve Trombosit/Lenfosit Oranlarının Seröz Over Kanseri Sağ Kalımındaki Yeri
Amaç: Seröz tip over kanserinde preoperatif sistemik inflamatuar belirteçlerin prognozu predikte etmedeki etkinliğini değerlendirmek ve sağ kalım ile ilişkilerini tanımlamak amaçlandı.Gereç ve Yöntemler: Çalışma grubu seröz tip over kanseri nedeniyle tedavisi yapılan 86 hastadan oluşturuldu. Hastalara ait veriler retrospektif olarak tarandı. Preoperatif inflamatuar belirteçler olarak nötrofil/lenfosit oranı (NLO), lenfosit/monosit oranı (LMO) ve trombosit/lenfosit oranları (TLO) kullanıldı. Hastalar NLO, LMO ve TLO değerlerine göre yüksek veya düşük riskli olarak gruplandırıldı. Grupları kategorize etmede sınır değer olarak ortanca değerler kullanıldı. Klinik, cerrahi ve patolojik değişkenlerle birlikte NLO, LMO, TLO değerlerinin hastalıksız sağ kalım (HSK) ve genel sağ kalım (GSK) üzerindeki etkisi incelendi.Bulgular: Hastaların ortanca yaşları 58.03 (aralık; 25-80) yıldı. Evre 12 hastada evre I-II ve 74 hastada evre III-IV’tü. Ortanca takip süresi 29.45 aydı (aralık; 1-63) ve bu süre içerisinde 21 (%24,4) hastada rekürrens geliştiği ve 15 (%17,4) hastanın hastalıktan dolayı öldüğü tespit edildi. Tüm çalışma grubunda ortalama HSK süresi 46.32±3,00 ay ve GSK süresi 51.30±2.43 aydı. HSK için; omentum metastazı, dalak metastazı, diyafragma metastazı, kolon metastazı, cerrahi sonuç ve adjuvant tedavi başarısı, GSK için; omentum metastazı, hastanın adjuvant tedavi alıp almaması ve adjuvan tedavi başarısı anlamlıydı (p0.05).Sonuç: Seröz tip over kanserinde, preoperatif inflamatuar belirteçlerin hastalıksız sağ kalımı ve genel sağ kalımı öngörmede yönlendirici olmadığı tespit edilmiştir.
- 28 February 2021
- Published by Balikesir Medical Journal in Balıkesir Medical Journal
- Vol. 5 (1) , 43-53
Preoperatif Nötrofil/Lenfosit, Lenfosit/Monosit ve Trombosit/Lenfosit Oranlarının Seröz Over Kanseri Sağ Kalımındaki Yeri
Amaç: Seröz tip over kanserinde preoperatif sistemik inflamatuar belirteçlerin prognozu predikte etmedeki etkinliğini değerlendirmek ve sağ kalım ile ilişkilerini tanımlamak amaçlandı.Gereç ve Yöntemler: Çalışma grubu seröz tip over kanseri nedeniyle tedavisi yapılan 86 hastadan oluşturuldu. Hastalara ait veriler retrospektif olarak tarandı. Preoperatif inflamatuar belirteçler olarak nötrofil/lenfosit oranı (NLO), lenfosit/monosit oranı (LMO) ve trombosit/lenfosit oranları (TLO) kullanıldı. Hastalar NLO, LMO ve TLO değerlerine göre yüksek veya düşük riskli olarak gruplandırıldı. Grupları kategorize etmede sınır değer olarak ortanca değerler kullanıldı. Klinik, cerrahi ve patolojik değişkenlerle birlikte NLO, LMO, TLO değerlerinin hastalıksız sağ kalım (HSK) ve genel sağ kalım (GSK) üzerindeki etkisi incelendi.Bulgular: Hastaların ortanca yaşları 58.03 (aralık; 25-80) yıldı. Evre 12 hastada evre I-II ve 74 hastada evre III-IV’tü. Ortanca takip süresi 29.45 aydı (aralık; 1-63) ve bu süre içerisinde 21 (%24,4) hastada rekürrens geliştiği ve 15 (%17,4) hastanın hastalıktan dolayı öldüğü tespit edildi. Tüm çalışma grubunda ortalama HSK süresi 46.32±3,00 ay ve GSK süresi 51.30±2.43 aydı. HSK için; omentum metastazı, dalak metastazı, diyafragma metastazı, kolon metastazı, cerrahi sonuç ve adjuvant tedavi başarısı, GSK için; omentum metastazı, hastanın adjuvant tedavi alıp almaması ve adjuvan tedavi başarısı anlamlıydı (p0.05).Sonuç: Seröz tip over kanserinde, preoperatif inflamatuar belirteçlerin hastalıksız sağ kalımı ve genel sağ kalımı öngörmede yönlendirici olmadığı tespit edilmiştir.
- 1 June 2017
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 6 (2) , 270-276
Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors
To validate the oncological safety of fertility preservation in malignant ovarian germ cell tumors (MOGCTs) and to define the significance of maximal cytoreduction in early stage MOGCTs. Sixty-nine patients with stage I and II MOGCTs who underwent surgical treatment were included in the study. Fertility-sparing surgery is defined as conservative surgery and hysterectomy and contralateral salpingo-oophorectomy were defined as definitive surgery. Both surgical approaches involved lymphadenectomy and omentectomy. Most patients received platinum-based combinations for adjuvant therapy. Survival outcomes of the conservative surgery group were compared with the definitive surgery group. Median age of the study group was 21 years (range: 12-40 years). Median tumor size measured 150 mm (range, 20-300 mm). Surgery type (conservative surgery vs. definitive surgery) and lymphadenectomy (performed vs. not performed) were insignificant for the recurrence (p = 0.758, p = 0.271). However, surgical outcome (maximal vs. optimal and suboptimal) and type of tumor (dysgerminoma vs. nondysgerminoma) determined the recurrence (p = 0.001, p = 0.021). Fertility-conserving approach is safe in early stage MOGCTs. However, maximal cytoreduction should be achieved in this group of patients, without conceding fertility-conserving approach. On the other hand, development of chemotherapy options with less gonadotoxic effects, but equal or stronger efficiency in comparison with platinum-based chemotherapy, will certainly facilitate management of this patient group.
- 1 June 2017
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 6 (2) , 270-276
Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors
To validate the oncological safety of fertility preservation in malignant ovarian germ cell tumors (MOGCTs) and to define the significance of maximal cytoreduction in early stage MOGCTs. Sixty-nine patients with stage I and II MOGCTs who underwent surgical treatment were included in the study. Fertility-sparing surgery is defined as conservative surgery and hysterectomy and contralateral salpingo-oophorectomy were defined as definitive surgery. Both surgical approaches involved lymphadenectomy and omentectomy. Most patients received platinum-based combinations for adjuvant therapy. Survival outcomes of the conservative surgery group were compared with the definitive surgery group. Median age of the study group was 21 years (range: 12-40 years). Median tumor size measured 150 mm (range, 20-300 mm). Surgery type (conservative surgery vs. definitive surgery) and lymphadenectomy (performed vs. not performed) were insignificant for the recurrence (p = 0.758, p = 0.271). However, surgical outcome (maximal vs. optimal and suboptimal) and type of tumor (dysgerminoma vs. nondysgerminoma) determined the recurrence (p = 0.001, p = 0.021). Fertility-conserving approach is safe in early stage MOGCTs. However, maximal cytoreduction should be achieved in this group of patients, without conceding fertility-conserving approach. On the other hand, development of chemotherapy options with less gonadotoxic effects, but equal or stronger efficiency in comparison with platinum-based chemotherapy, will certainly facilitate management of this patient group.
- 1 May 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (4) , 748-753
Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer
- 1 May 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (4) , 748-753
Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer
- 20 March 2017
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 37 (5) , 649-654
Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
The aim of this study was to evaluate the efficacy and toxicity profile of oral etoposide (50 mg/day, days 1–14, every 3 weeks) in recurrent platinum-resistant epithelial ovarian cancer (EOC). 52 recurrent platinum-resistant EOC patients followed up in four centres between April 2000 and December 2013 were analysed retrospectively. There was response in a total of 21 patients [partial response (PR) and stable disease (SD)], 12 of them used etoposide in second and third, and 9 of them used it in fourth- to fifth-lines of treatment. The overall response rate was 19.2% and clinical benefit rate was 40.4% [PR (19.2%), SD (21.2%)]. Median overall survival (OS) and progression-free survival (PFS) was 9.95 months (95%CI, 0.2–19.7 months) and 3.2 months (95%CI 2.6–3.8 months), respectively. Grade III–IV haematologic and non-haematologic adverse events were observed in 7 (13.4%) patients. We consider that oral etoposide (50 mg/day, days 1–14, every 3 weeks) is an effective treatment with a manageable adverse effect profile in recurrent platinum-resistant EOC patients.
- 20 March 2017
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 37 (5) , 649-654
Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
The aim of this study was to evaluate the efficacy and toxicity profile of oral etoposide (50 mg/day, days 1–14, every 3 weeks) in recurrent platinum-resistant epithelial ovarian cancer (EOC). 52 recurrent platinum-resistant EOC patients followed up in four centres between April 2000 and December 2013 were analysed retrospectively. There was response in a total of 21 patients [partial response (PR) and stable disease (SD)], 12 of them used etoposide in second and third, and 9 of them used it in fourth- to fifth-lines of treatment. The overall response rate was 19.2% and clinical benefit rate was 40.4% [PR (19.2%), SD (21.2%)]. Median overall survival (OS) and progression-free survival (PFS) was 9.95 months (95%CI, 0.2–19.7 months) and 3.2 months (95%CI 2.6–3.8 months), respectively. Grade III–IV haematologic and non-haematologic adverse events were observed in 7 (13.4%) patients. We consider that oral etoposide (50 mg/day, days 1–14, every 3 weeks) is an effective treatment with a manageable adverse effect profile in recurrent platinum-resistant EOC patients.
- 1 February 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (2) , 315-325
Is Neurosurgery With Adjuvant Radiotherapy an Effective Treatment Modality in Isolated Brain Involvement From Endometrial Cancer?
- 1 February 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (2) , 315-325
Is Neurosurgery With Adjuvant Radiotherapy an Effective Treatment Modality in Isolated Brain Involvement From Endometrial Cancer?
- 1 January 2017
- Published by LookUs Bilisim A.S. in Acta Oncologica Turcica
- Vol. 50 (1) , 66-68
Endometrial Cancer in Bicornuate Uterus: Case Report
- 1 January 2017
- Published by LookUs Bilisim A.S. in Acta Oncologica Turcica
- Vol. 50 (1) , 66-68
Endometrial Cancer in Bicornuate Uterus: Case Report
- 1 January 2017
- Published by LookUs Bilisim A.S. in Kafkas Journal of Medical Sciences
- Vol. 7 (3) , 251-254
Primary Adenocarcinoma of the Endometrium Coincide with Tuberculous Lymphadenitis
- 1 January 2017
- Published by LookUs Bilisim A.S. in Kafkas Journal of Medical Sciences
- Vol. 7 (3) , 251-254
Primary Adenocarcinoma of the Endometrium Coincide with Tuberculous Lymphadenitis
- 6 December 2016
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 37 (1) , 93-96
Uterine adenosarcomas: A dual-institution experience
There has been limited literature about treatment and follow-up strategies of uterine adenosarcomas because of their rare nature. For this study we retrospectively investigated the medical database of the two major womens' health hospitals in Turkey. A total of 15 patients were identified from the hospital's database. Median follow-up was 86.43 months for all patients. Seven out of 15 patients had recurrences during their follow-up. Among these 7 patients, 4 of them had stage IA disease. Median Disease Free Survival (DFS) and Overall Survival (OS) were calculated as 41.47 and 57.21 months, respectively. According to our study, polypoid tumours confined to the uterus with superficial myometrial invasion can be treated without comprehensive surgical staging. We believe that, publishing all the data in an organised manner even though they are small in size, gives us an opportunity to design meta-analysis for the development of more appropriate treatment strategies.
- 6 December 2016
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 37 (1) , 93-96
Uterine adenosarcomas: A dual-institution experience
There has been limited literature about treatment and follow-up strategies of uterine adenosarcomas because of their rare nature. For this study we retrospectively investigated the medical database of the two major womens' health hospitals in Turkey. A total of 15 patients were identified from the hospital's database. Median follow-up was 86.43 months for all patients. Seven out of 15 patients had recurrences during their follow-up. Among these 7 patients, 4 of them had stage IA disease. Median Disease Free Survival (DFS) and Overall Survival (OS) were calculated as 41.47 and 57.21 months, respectively. According to our study, polypoid tumours confined to the uterus with superficial myometrial invasion can be treated without comprehensive surgical staging. We believe that, publishing all the data in an organised manner even though they are small in size, gives us an opportunity to design meta-analysis for the development of more appropriate treatment strategies.
- 1 September 2016
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 5 (3) , 261-266
Embryonal Rhabdomyosarcoma of the Cervix in Young Women
Purpose: Cervical rhabdomyosarcoma (RMS) is an extremely rare disease, and there is no precise criteria related to its treatment. Our aim was to describe the clinical and pathological features of cervical RMS. Methods: Clinicopathological data of cases with cervical RMS were retrieved from the computerized database of Etlik Zubeyde Hanim Women's Health and Research Hospital. Five patients with the diagnosis of cervical RMS who underwent surgical treatment and had adjuvant chemotherapy between 2003 and 2015 were included in the study. Results: Mean age of patients at the time of diagnosis was 15.8 ± 2 years. Abnormal vaginal bleeding and mass were the most common complaints. All patients had embryonal rhabdomyosarcoma (E-RMS) and Group I disease according to the Intergroup Rhabdomyosarcoma Study Group clinical classification system. Cone biopsy and polypectomy were performed in four patients, and radical abdominal hysterectomy with pelvic–paraaortic lymphadenectomy was performed in one patient. Chemotherapy consisting vincristine, dactinomycin, and cyclophosphamide was given as an adjuvant therapy. Estimated 5-year overall survival and disease-free survival were 40% and 37.5%, respectively. Conclusions: We report a small series of patients with cervical E-RMS who were treated with surgery and adjuvant chemotherapy. Although all patients in the present study had good prognostic factors, survival was not as good as indicated in the literature. Diminished survival of our patient group may be associated with underlying molecular and pathophysiologic differences other than stage and histological subtype that have not been discovered yet.
- 1 September 2016
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 5 (3) , 261-266
Embryonal Rhabdomyosarcoma of the Cervix in Young Women
Purpose: Cervical rhabdomyosarcoma (RMS) is an extremely rare disease, and there is no precise criteria related to its treatment. Our aim was to describe the clinical and pathological features of cervical RMS. Methods: Clinicopathological data of cases with cervical RMS were retrieved from the computerized database of Etlik Zubeyde Hanim Women's Health and Research Hospital. Five patients with the diagnosis of cervical RMS who underwent surgical treatment and had adjuvant chemotherapy between 2003 and 2015 were included in the study. Results: Mean age of patients at the time of diagnosis was 15.8 ± 2 years. Abnormal vaginal bleeding and mass were the most common complaints. All patients had embryonal rhabdomyosarcoma (E-RMS) and Group I disease according to the Intergroup Rhabdomyosarcoma Study Group clinical classification system. Cone biopsy and polypectomy were performed in four patients, and radical abdominal hysterectomy with pelvic–paraaortic lymphadenectomy was performed in one patient. Chemotherapy consisting vincristine, dactinomycin, and cyclophosphamide was given as an adjuvant therapy. Estimated 5-year overall survival and disease-free survival were 40% and 37.5%, respectively. Conclusions: We report a small series of patients with cervical E-RMS who were treated with surgery and adjuvant chemotherapy. Although all patients in the present study had good prognostic factors, survival was not as good as indicated in the literature. Diminished survival of our patient group may be associated with underlying molecular and pathophysiologic differences other than stage and histological subtype that have not been discovered yet.